$SPPI News
Last published 3y ago
- 3y agoASRTSPPIAssertio Holdings, Inc. Closes Spectrum Pharmaceuticals TransactionGlobeNewswireCombination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to
- 3y agoASRTSPPIAssertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum PharmaceuticalsGlobeNewswireStockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON, July 27, 2023
- 3y agoASRTSPPIIndependent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote "FOR" Proposed Transaction with Assertio Holdings, Inc.Business WireRecommendations from the Nation's Leading Independent Proxy Advisory Firms Recognize Value Creation Opportunity for Spectrum Stockholders and Strength of the Combined Company Spectrum Pharmaceuticals, Inc.
- 3y agoARNCEMBKSPPISYNHMoore Kuehn Encourages SYNH, SPPI, ARNC and EMBK Investors to Contact Law FirmGlobeNewswireNEW YORK, July 03, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoSPPISpectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementBusiness WireSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company"), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written
- 3y agoASRTSPPISpectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate UpdateBusiness Wire-- Q1 2023 net sales of $15.6 million, an increase of 54% compared to Q4 2022 -- -- Company to be acquired by Assertio Holdings, Inc., delivering value to stakeholders in an all stock and contingent value rights (CVR)
- 3y agoGLOPHOTHHSKASPPIMoore Kuehn Encourages HOTH, HSKA, SPPI, and GLOP Investors to Contact Law FirmPR NewswireNEW YORK, April 28, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoASRTSPPIAssertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR TransactionGlobeNewswireComplementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio's Omni-Channel Digital Sales
- 3y agoSPPISpectrum Pharmaceuticals, Inc. (SPPI) Q4 2022 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoSPPISpectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate UpdateBusiness Wire-- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT
- 3y agoSPPISpectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate UpdateBusiness WireSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022
- 3y agoSPPISpectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid ServicesBusiness WireSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst)
- 3y agoSPPISpectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial ResultsBusiness Wire-- Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million -- -- Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through
- 3y agoSPPISpectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial StaffBusiness Wire-- Commercial employee (non-executive) who was hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection is the recipient of this grant -- Spectrum Pharmaceuticals (NASDAQ:SPPI), a
- 3y agoSPPISpectrum Pharmaceuticals Announces Management ChangesBusiness WireSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel, M.D., Executive Vice President and Chief Medical
- 3y agoSPPISpectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial StaffBusiness Wire-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant -- Spectrum Pharmaceuticals (NASDAQ:SPPI), a
- 3y agoSPPINational Law Firm Investigating Spectrum Pharmaceuticals, Inc. Over Alleged False/Misleading Statements Regarding New Drug ApplicationPR NewswireComplaint Alleges Spectrum Pharmaceuticals Failed to Disclose Negative Data from Clinical Trials ONTARIO, Calif., Dec. 9, 2022 /PRNewswire/ -- McCune law Group, McCune Wright Arevalo Vercoski Kusel Weck Brandt APC (MLG)
- 3y agoSPPISpectrum Pharmaceuticals' ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth FactorsBusiness WireSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive
- 3y agoSPPISpectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial StaffBusiness Wire-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant -- Spectrum Pharmaceuticals (NASDAQ:SPPI), a
- 3y agoSPPIKaplan Fox Continues to Investigate Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) - INVESTOR UPDATEGlobeNewswireNEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is continuing to investigate claims on behalf of investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company")
- 3y agoSPPIKaplan Fox Continues to Investigate Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) - INVESTOR UPDATEGlobeNewswireNEW YORK, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is continuing to investigate claims on behalf of investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company")
- 3y agoSPPISpectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injectionBusiness Wire— Immediately de-prioritizes poziotinib program, accelerates cost reductions, including 75% reduction in R&D related workforce — — Spectrum to explore strategic alternatives for the poziotinib program, including
- 3y agoSPPIKaplan Fox Investigates Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)GlobeNewswireNEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company")
- 4y agoSPPISpectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate UpdateBusiness WireSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2022 financial
- 4y agoSPPISpectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) InjectionBusiness Wire-- Distribution partners stocked with product and ready to sell into estimated $2 billion market -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company"), a biopharmaceutical company focused on
- 4y agoSPPISpectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at ClosingBusiness Wire-- Multiple tranche debt financing provides Spectrum with up to $65 million -- -- Funding provides additional capital to optimize commercial launch of ROLVEDON™ -- -- Cash runway extended through 2024 -- Spectrum Pharmaceuticals, Inc. (NASDAQ
- 4y agoSPPISpectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee MeetingBusiness WireSpectrum Pharmaceuticals (NASDAQ:SPPI) ("Spectrum" or the "Company"), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee (
- 4y agoSPPISpectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022Business WireSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutati
- 4y agoSPPISpectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) InjectionBusiness WireFirst novel Long-Acting GCSF (LA-GCSF) product approved in over 20 years ROLVEDON™ developed using proprietary LAPSCOVERY™ technology with a differentiated molecular structure and proven safety and efficacy profile Commercial team ready to lau
- 4y agoSPPISpectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022Business WireSpectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small
- 4y agoSPPISpectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateBusiness WireEflapegrastim BLA under FDA review; PDUFA date September 9, 2022 FDA completes re-inspection of drug substance manufacturing facility for eflapegrastim Poziotinib NDA under FDA review with ODAC meeting on September 22, 2022 Management to host w
- 4y agoSPPISpectrum Pharmaceuticals (SPPI) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsSPPI earnings call for the period ending June 30, 2022.
- 4y agoSPPISpectrum Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate UpdateBusiness WireSpectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on T
- 4y agoSPPISpectrum Pharmaceuticals to Participate in Two Upcoming Investor ConferencesBusiness WireSpectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in two upcoming investor conferences: A fireside chat presentation at the Jefferi
- 4y agoSPPISpectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment ResponseBusiness WireReduced circulating tumor DNA (ctDNA) and circulating free DNA (cfDNA) levels were associated with tumor shrinkage in patients that responded to poziotinib treatment Poziotinib has received Fast Track designation from FDA and a Prescription Drug User
- 4y agoSPPISpectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment ConferenceBusiness WireSpectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference, to be held virtually and
- 4y agoSPPISpectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateBusiness WireResubmitted eflapegrastim BLA accepted for review by the FDA, PDUFA date September 9, 2022 Poziotinib NDA under review by FDA with PDUFA date of November 24, 2022 and will be discussed at ODAC meeting in September Positive poziotinib results in tr
- 4y agoSPPISpectrum Pharmaceuticals (SPPI) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsSPPI earnings call for the period ending March 31, 2022.
- 4y agoSPPISpectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial OfficerBusiness WireSpectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022. Ms. Brennan has served on Spectrum's
- 4y agoSPPISpectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate UpdateBusiness WireSpectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update on Th
- 4y agoSPPISpectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of DirectorsBusiness WireSpectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of fin
- 4y agoBILIHOTHHYMCMSP+1Thinking about buying stock in Hoth Therapeutics, Spectrum Pharmaceuticals, Datto Holding, Bilibili, or Hycroft Mining?PR NewswireNEW YORK, April 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOTH, SPPI, MSP, BILI, and HYMC.
- 4y agoSPPISpectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for EflapegrastimBusiness WireFDA has assigned September 9, 2022 as the PDUFA date Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the resubmitted Biologics License Application (BLA) for ef
- 4y agoSPPISpectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual MeetingBusiness WireSpectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced abstract acceptance with a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual M
- 4y agoBVXVHEPSNKLASPPI+1Thinking about buying stock in Nikola Corp, D-Market Electronic Services, Biondvax Pharmaceuticals, Trip.com, or Spectrum Pharmaceuticals?PR NewswireNEW YORK, March 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKLA, HEPS, BVXV, TCOM, and SPPI.
- 4y agoCELZLBPSONCYREVB+1Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast CancerPR NewswirePALM BEACH, Fla., March 24, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and mor
- 4y agoBBSPPITDUPUGP+1Thinking about buying stock in BlackBerry, VEON, Ultrapar Participacoes, Spectrum Pharmaceuticals, or ThredUp?PR NewswireNEW YORK, March 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BB, VEON, UGP, SPPI, and TDUP. T
- 4y agoSPPISpectrum Pharmaceuticals Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Corporate UpdateBusiness WireEflapegrastim BLA resubmitted to FDA Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 20 insertion mutations, PDUFA date November 24, 2022 Positive poziotinib results in treatment naïve patients
- 4y agoSPPISpectrum Pharmaceuticals (SPPI) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsSPPI earnings call for the period ending December 31, 2021.
- 4y agoSPPISpectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate UpdateBusiness WireSpectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2021 financial results and provide a corpora